 SOUTH SAN FRANCISCO, Calif., May 19, 2021 PRNewswire -- Sutro Biopharma, Inc. NASDAQ: STRO, a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced additional data from the Companys dose-escalation cohort of the Phase 1 study of STRO-002, a folate receptor alpha FolRα targeting antibody-drug conjugate ADC for patients with advanced, progressive ovarian cancer; the data will also be presented as a poster at the American Society of Clinical Oncology ASCO 2021 Annual Meeting to be held on June 4-8, 2021. 